H Mei1, C Yu, K K Chan. 1. Division of Pharmaceutics, College of Pharmacy, Comprehensive Cancer Center, Ohio State University, Columbus 43210, USA.
Abstract
PURPOSE: To develop a simple and efficient method for the synthesis and purification of NB1-lipid-modified-insulin without the use of protecting agents. METHODS: Bovine insulin was allowed to react with cis-9-hexadecenal in an aqueous-organic medium in the presence of NaBH3CN at room temperature overnight. HPLC and ESI LC/MS coupled with dithiothreitol and trypsin treatment were employed for product identification and optimization. The product was purified by a differential C18 solid-phase extraction. The biological effects of the modified insulin were evaluated by receptor binding assay and hypoglycemic effect measurement. RESULTS: NB1-cis-9-hexadecenyl insulin was synthesized by a one-step reductive alkylation in sodium salicylate and isopropanol solution in high yield (80%). The site selectivity and yield of the reaction were found to be affected by pH, medium, and insulin-to-aldehyde ratio. After solid phase extraction, the purity was found to be approximately 98%. This derivative showed a Kd to the insulin receptor of 5.72x10(-9) M and a significantly slower glucose lowering rate than insulin. CONCLUSIONS: NB1-hexadecenyl insulin was synthesized by reductive alkylation without the use of protective agents in high yield. NB1-hexadecenyl insulin retained significant binding affinity to insulin receptor and showed a pronounced hypoglycemic effect.
PURPOSE: To develop a simple and efficient method for the synthesis and purification of NB1-lipid-modified-insulin without the use of protecting agents. METHODS:Bovineinsulin was allowed to react with cis-9-hexadecenal in an aqueous-organic medium in the presence of NaBH3CN at room temperature overnight. HPLC and ESI LC/MS coupled with dithiothreitol and trypsin treatment were employed for product identification and optimization. The product was purified by a differential C18 solid-phase extraction. The biological effects of the modified insulin were evaluated by receptor binding assay and hypoglycemic effect measurement. RESULTS: NB1-cis-9-hexadecenyl insulin was synthesized by a one-step reductive alkylation in sodium salicylate and isopropanol solution in high yield (80%). The site selectivity and yield of the reaction were found to be affected by pH, medium, and insulin-to-aldehyde ratio. After solid phase extraction, the purity was found to be approximately 98%. This derivative showed a Kd to the insulin receptor of 5.72x10(-9) M and a significantly slower glucose lowering rate than insulin. CONCLUSIONS: NB1-hexadecenyl insulin was synthesized by reductive alkylation without the use of protective agents in high yield. NB1-hexadecenyl insulin retained significant binding affinity to insulin receptor and showed a pronounced hypoglycemic effect.
Authors: S R Myers; F E Yakubu-Madus; W T Johnson; J E Baker; T S Cusick; V K Williams; F C Tinsley; A Kriauciunas; J Manetta; V J Chen Journal: Diabetes Date: 1997-04 Impact factor: 9.461
Authors: J Markussen; S Havelund; P Kurtzhals; A S Andersen; J Halstrøm; E Hasselager; U D Larsen; U Ribel; L Schäffer; K Vad; I Jonassen Journal: Diabetologia Date: 1996-03 Impact factor: 10.122
Authors: A Kurtaran; S R Li; M Raderer; M Leimer; C Müller; J Pidlich; N Neuhold; P Hübsch; P Angelberger; W Scheithauer Journal: J Nucl Med Date: 1995-10 Impact factor: 10.057
Authors: Nikhil J Kavimandan; Elena Losi; Jeffrey J Wilson; Jennifer S Brodbelt; Nicholas A Peppas Journal: Bioconjug Chem Date: 2006 Nov-Dec Impact factor: 4.774